Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors – a Nordic cohort study.

Bookmark this %label%

To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients with psoriatic arthritis (PsA).From the Nordic clinical rheumatology registers (CRR) here: SRQ/ARTIS (Sweden), DANBIO […]

» Read more

Effect of adalimumab on axial manifestations in Japanese patients with psoriatic arthritis: a 24 week prospective, observational study.

Bookmark this %label%

PsA is characterized by enthesitis, synovitis and osseous involvement in the peripheral and axial joints. Few studies have examined axial involvement in PsA using imaging techniques. Here we examined axial […]

» Read more

Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.

Bookmark this %label%

To estimate the incidence of COVID-19 hospitalisation in patients with inflammatory rheumatic disease (IRD); in patients with rheumatoid arthritis (RA) treated with specific DMARDs; and the incidence of severe COVID-19 […]

» Read more

Sensitivity to change and clinical correlations of the novel DACtylitis glObal Sonographic (DACTOS) score in psoriatic arthritis.

Bookmark this %label%

The aim of the study is to assess the performance of the DACTOS (DACtylitis glObal Sonographic) score in a psoriatic arthritis (PsA) dactylitis clinical setting. In particular, we evaluated the […]

» Read more

Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.

Bookmark this %label%

To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA.All patients with PsA starting secukinumab or a TNFi in […]

» Read more

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Bookmark this %label%

MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of psoriatic arthritis (PsA).This phase 3b, […]

» Read more

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Bookmark this %label%

MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of psoriatic arthritis (PsA).This phase 3b, […]

» Read more

Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden.

Bookmark this %label%

We aimed to investigate the disease activity and overall disease burden of (subgroups of) patients with PsA using the Psoriatic Arthritis Disease Activity Score (PASDAS) in an already tightly monitored […]

» Read more

A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health.

Bookmark this %label%

Physical function is a core outcome in PsA. We examined the construct validity and responsiveness of three commonly used instruments to assess physical function in PsA: HAQ disability index (HAQ-DI), […]

» Read more

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.

Bookmark this %label%

Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at […]

» Read more

Comparing the visual analogue scale (VAS) and the numerical rating scale (NRS) in patient reported outcomes in psoriatic arthritis.

Bookmark this %label%

Patient self-report scales are invaluable in psoriatic arthritis (PsA), as they allow physicians to rapidly assess patient perspectives of disease activity. We aimed to assess the agreement of the visual […]

» Read more

IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors.

Bookmark this %label%

To determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and explore mechanistic links between diseased tissue pathology and clinical outcomes.Twenty-seven active PsA […]

» Read more

Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk.

Bookmark this %label%

Fat mass distribution, especially in the abdominal visceral region, has been rarely evaluated in patients with PsA or psoriasis (PsO).Patients with PsA and patients with PsO alone were evaluated and […]

» Read more

Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.

Bookmark this %label%

To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA.In this retrospective, national, […]

» Read more

Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk.

Bookmark this %label%

Fat mass distribution, especially in the abdominal visceral region, has been rarely evaluated in patients with PsA or psoriasis (PsO).Patients with PsA and patients with PsO alone were evaluated and […]

» Read more

Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.

Bookmark this %label%

To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA.In this retrospective, national, […]

» Read more

Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study.

Bookmark this %label%

To estimate the incidence and strength of association of extra-articular manifestations [EAMs, here: anterior uveitis (AU), IBD and psoriasis] in patients with AS, undifferentiated SpA (uSpA) and PsA, compared with […]

» Read more

Relation between fatigue and ACR response in patients with psoriatic arthritis treated with TNFi therapy: a population-based cohort study.

Bookmark this %label%

The objective of this population-based cohort study was to investigate the association of fatigue with disease activity and drug survival in PsA patients receiving their first tumor necrosis factor inhibitor […]

» Read more

Risk of osteoarthritis in an incident cohort of people with psoriatic arthritis: a population-based cohort study.

Bookmark this %label%

To determine the risk of a diagnosis of osteoarthritis (OA) in psoriatic arthritis (PsA) patients compared to patients with psoriasis and a general population cohort.Incident PsA patients aged 18-89 years […]

» Read more

Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results.

Bookmark this %label%

Therapeutic response was evaluated among new apremilast, methotrexate, or biologic disease-modifying anti-rheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA).Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment […]

» Read more

Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic.

Bookmark this %label%

To assess concerns and healthcare-related behaviors of patients with autoimmune rheumatic diseases during the COVID-19 pandemic.Adults from the United States with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), […]

» Read more

The causal effect of interleukin-17 on the risk of psoriatic arthritis: a Mendelian randomization study.

Bookmark this %label%

To determine causal associations between genetically predicted TNF-α, IL-12p70 and IL-17 levels and risk of PsA.The publicly available summary-level findings from genome-wide association studies (GWAS) was used to identify loci […]

» Read more

The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids.

Bookmark this %label%

People with PsA are at increased risk of cardiovascular disease. The objective of this study was to quantify the risk of myocardial infarction (MI), stroke and revascularizations in people with […]

» Read more

Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity – a cross-sectional study.

Bookmark this %label%

To compare body composition in PsA with metabolic disease free (MDF) controls and type 2 diabetes and assess body-composition predicted propensity for cardiometabolic disease.Detailed MRI body composition profiles of 26 […]

» Read more

Residual disease burden in axial Spondyloarthritis and Psoriatic Arthritis patients despite low disease activity states in a multi-ethnic Asian population.

Bookmark this %label%

To evaluate the burden of residual disease in patients with axial SpondyloArthritis (axSpA) or Psoriatic Arthritis (PsA) who achieved low disease activity status.We used baseline data from a clinic registry […]

» Read more

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.

Bookmark this %label%

To compare the efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA).Adult patients with active PsA and inadequate response to, […]

» Read more

PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis.

Bookmark this %label%

Our aim is to understand clinical characteristics, real-life treatment strategies, outcomes of early PsA patients and determine the differences between the inception and established PsA cohorts.PsArt-ID (Psoriatic Arthritis- International Database) […]

» Read more

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.

Bookmark this %label%

The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 […]

» Read more

Soluble Low-density Lipoprotein Receptor-related Protein 1 in Juvenile Idiopathic Arthritis.

Bookmark this %label%

This study aimed to expand knowledge about soluble low-density lipoprotein receptor-related protein 1(sLRP1) in juvenile idiopathic arthritis (JIA) by determining associations of sLRP1 levels in non-systemic JIA patients with clinical […]

» Read more

Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Bookmark this %label%

To examine the association of nail psoriasis with disease activity, quality of life, and work productivity in patients with psoriatic arthritis (PsA).All patients with PsA who enrolled in the Corrona […]

» Read more
1 2 3 5